KR900013949A - 정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도 - Google Patents

정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도 Download PDF

Info

Publication number
KR900013949A
KR900013949A KR1019900002912A KR900002912A KR900013949A KR 900013949 A KR900013949 A KR 900013949A KR 1019900002912 A KR1019900002912 A KR 1019900002912A KR 900002912 A KR900002912 A KR 900002912A KR 900013949 A KR900013949 A KR 900013949A
Authority
KR
South Korea
Prior art keywords
compound
tetrahydro
cis
naphthalene amine
dichlorophenyl
Prior art date
Application number
KR1019900002912A
Other languages
English (en)
Other versions
KR920005810B1 (ko
Inventor
케니쓰 코에 빌리
Original Assignee
알렌 제이.스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23244506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900013949(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알렌 제이.스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이.스피겔
Publication of KR900013949A publication Critical patent/KR900013949A/ko
Application granted granted Critical
Publication of KR920005810B1 publication Critical patent/KR920005810B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 정신병치료, 소염 또는 면역억제 효과량의 하기 일반식(I)의 화합물 또는 그의 약학적으로 허용되는 산부가 염을 정신병치료, 소염 또는 면역억제를 필요로 하는 포유동물에게 투여함을 포함하는, 상기 포유동물에서 정신병치료, 소염 또는 면역억제 효과를 얻는 방법 :
    상기식에서, R1은 수소 및 C1내지 C3알킬로 구성된 그룹중에서 선택되고, R2는 C1내지 C3알킬이고, Z는(여기에서, X와 Y는 각각 독립적으로 수소, 플루오로, 크로로, 브로모, 트리플루오로메틸, C1내지 C3의 알콕시 및 시아노로 구성된 그룹중에서 선택되고, X와 Y중 적어도 하나는 수소가 아니다)이고, W는 수소, 플루오로, 클로로, 브로모, 트리플루오로메틸 및 C1내지 C3의 알콕시로 구성된 그룹중에서 선택된다.
  2. 제1항에 있어서, 상기 화합물이 시스 또는 트란스 이성체인 방법.
  3. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N-메틸-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  4. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N-메틸-4-(4-클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  5. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N-메틸-(3-트리플루오로메틸, 4-클로로-페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  6. 제1항에 있어서, 상기 화합물이 트란스-(1S) (1R)-N-메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  7. 제1항에 있어서, 상기 화합물이 트란스-(1S) (4S)-N-메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  8. 제1항에 있어서, 상기 화합물이 시스-(1S) (4R)-N-메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  9. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-아미노-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  10. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N,N-디메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  11. 정신병치료, 소염 또는 면역억제 효과량의 제1항의 화합물과 약학적으로 허용되는 담체를 함체 포함하는 정신병 및 염증치료와 면역억제 유도를 위한 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900002912A 1989-03-07 1990-03-06 정신병 치료제 KR920005810B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US320,014 1989-03-07
US07/320,014 US4981870A (en) 1989-03-07 1989-03-07 Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US320.014 1989-03-07

Publications (2)

Publication Number Publication Date
KR900013949A true KR900013949A (ko) 1990-10-22
KR920005810B1 KR920005810B1 (ko) 1992-07-20

Family

ID=23244506

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900002912A KR920005810B1 (ko) 1989-03-07 1990-03-06 정신병 치료제

Country Status (17)

Country Link
US (2) US4981870A (ko)
EP (1) EP0386997B1 (ko)
JP (2) JPH0714870B2 (ko)
KR (1) KR920005810B1 (ko)
AT (1) ATE150299T1 (ko)
AU (1) AU610036B2 (ko)
CA (1) CA2011428C (ko)
DE (1) DE69030212T2 (ko)
DK (1) DK0386997T3 (ko)
HU (1) HU221624B1 (ko)
IE (1) IE81047B1 (ko)
IL (1) IL93576A (ko)
MY (1) MY106272A (ko)
NZ (1) NZ232800A (ko)
PH (1) PH26542A (ko)
PT (1) PT93351B (ko)
ZA (1) ZA901743B (ko)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
CA2071897A1 (en) * 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
AU7177694A (en) * 1993-06-23 1995-01-17 Cambridge Neuroscience, Inc. Sigma receptor ligands and the use thereof
ES2074946B1 (es) * 1993-07-19 1996-06-16 Ferrer Int Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
EA002482B1 (ru) 1997-07-01 2002-06-27 Пфайзер Инк. Соли сертралина и лекарственные формы с длительным высвобождением сертралина
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
AU1724301A (en) 1999-12-23 2001-07-09 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
US20030129186A1 (en) 2001-07-25 2003-07-10 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US6988556B2 (en) * 2002-02-19 2006-01-24 Halliburton Energy Services, Inc. Deep set safety valve
KR101165549B1 (ko) * 2002-09-16 2012-07-19 선오비온 파마슈티컬스 인코포레이티드 트랜스 ４－（３，４－디클로로페닐）－１，２，３，４－테트라하이드로－１－나프탈렌아민을 사용한 ｃｎｓ 장애의 치료
WO2004024130A2 (en) * 2002-09-16 2004-03-25 Sepracor, Inc. TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
NZ548212A (en) * 2003-12-29 2010-07-30 Sepracor Inc Pyrrole and pyrazole DAAO inhibitors
PT1889198E (pt) 2005-04-28 2015-03-06 Proteus Digital Health Inc Sistema fármaco-informático
CA2957667A1 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
CA2636275C (en) * 2006-01-06 2013-02-12 Sepracor Inc. Tetralone-based monoamine reuptake inhibitors
ES2594156T3 (es) * 2006-01-06 2016-12-16 Sunovion Pharmaceuticals Inc. Cicloalquilaminas como inhibidores de la recaptación de monoaminas
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2816024B8 (en) * 2006-03-31 2018-04-04 Sunovion Pharmaceuticals Inc. Chiral amines
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2043745A2 (en) * 2006-05-31 2009-04-08 SEPRACOR Inc Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
WO2008089453A2 (en) * 2007-01-18 2008-07-24 Sepracor Inc. Inhibitors of d-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
BRPI0811639A2 (pt) 2007-05-31 2014-09-30 Sepracor Inc Cicloaquilaminas fenil substituídas como inibidores da recaptação de monoamina
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2015175514A1 (en) * 2014-05-13 2015-11-19 Sunovion Pharmaceuticals Inc. Methods and compositions of dasotraline for treatment of adhd
AU2015259346A1 (en) * 2014-05-13 2016-12-08 Sunovion Pharmaceuticals Inc. Dosage of dasotraline and method for treatment of ADHD
WO2016046669A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of depression and neurological diseases
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
FR3071726B1 (fr) * 2017-09-29 2020-09-04 Univ Paris Sud Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420472A (en) * 1972-09-27 1976-01-07 Pfizer Aminophenyltetralin compounds
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS59497B2 (ja) * 1979-11-01 1984-01-07 フアイザ−・インコ−ポレ−テツド トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants

Also Published As

Publication number Publication date
HU901325D0 (en) 1990-05-28
CA2011428C (en) 1994-11-08
IE900798L (en) 1990-09-07
JPH0714870B2 (ja) 1995-02-22
JPH07173056A (ja) 1995-07-11
CA2011428A1 (en) 1990-09-07
PT93351B (pt) 1996-03-29
IE81047B1 (en) 1999-12-01
NZ232800A (en) 1997-07-27
DK0386997T3 (da) 1997-04-14
EP0386997A3 (en) 1992-04-29
ATE150299T1 (de) 1997-04-15
US5061728A (en) 1991-10-29
EP0386997A2 (en) 1990-09-12
EP0386997B1 (en) 1997-03-19
MY106272A (en) 1995-04-29
HU221624B1 (hu) 2002-12-28
HUT59000A (en) 1992-04-28
ZA901743B (en) 1991-10-30
AU610036B2 (en) 1991-05-09
KR920005810B1 (ko) 1992-07-20
PH26542A (en) 1992-08-19
DE69030212D1 (de) 1997-04-24
US4981870A (en) 1991-01-01
JP3020808B2 (ja) 2000-03-15
JPH02300121A (ja) 1990-12-12
IL93576A (en) 1995-12-08
PT93351A (pt) 1990-11-07
IL93576A0 (en) 1990-11-29
DE69030212T2 (de) 1997-06-26
AU5079690A (en) 1990-09-20

Similar Documents

Publication Publication Date Title
KR900013949A (ko) 정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도
NO148996C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-fenyl-1,2,3,4-tetrahydro-1-naftalenaminderivater
KR950017988A (ko) 치환 n- 피페리디노-피라졸-3-카르복사미드
KR950031074A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR930019655A (ko) 종양치료 조성물 및 치료방법
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
DK0722313T3 (da) Viskoelastiske sammensætninger af fluorerede organiske forbindelser
ECSP034815A (es) "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas"
PE20050130A1 (es) Compuestos organicos
AR029806A1 (es) Derivados de fenilo, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de la composicion farmaceutica y usos de estos derivados
AR018732A1 (es) Iminoazucares alquilados para prevenir, reducir o revertir la resistencia a la multidroga en el tratamiento quimioterapeutico y composicionfarmaceutica que los contiene.
CO5560559A2 (es) Formulacion de suspension oral estabilizada
BR9610350A (pt) Tratamentos contra piolhos e misturas, loções e lìquidos para pulverização, repelentes de insetos.
DK1127571T3 (da) Anvendelse af sertralin til at behandle posttraumatisk stresssygdom
AR012426A1 (es) Un compuesto de indazol amida, un procedimiento para prepararlo, compuestos intermediarios, y una composicion farmaceutica que comprende dicho compuesto de indazol amida.
KR950701223A (ko) 항허혈성(Anti-ichemic)약물
RU2004110041A (ru) Фармацевтическая композиция, содержащая габапентин или его аналог и альфа-аминоамид, и ее применение в качестве анальгетика
ES2180995T3 (es) Nuevos derivados de tiazolidina-2,4-diona substituidos, sus procedimientos de obtencion y las composiciones farmaceuticas que los contienen.
KR940005274A (ko) 쇼그렌(Sjoegren)증후군 치료제
KR950016723A (ko) 자가면역 질병의 억제 방법
ATE209177T1 (de) Von einem aromatischen oder heteroaromatischen radikal substituierte biphenylderivate und diese enthaltende pharmaceutische und kosmetische compositionen
KR930005972A (ko) N-알킬-3-페닐-3-(2-알킬티오페녹시)프로필아민
AR062112A1 (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina
PE20021060A1 (es) Empleo de amidas de acidos antranilicos como medicamento para el tratamiento de arritmias, asi como preparados farmaceuticos que las contienen
DK173553B1 (da) Aminosyrederivater, antikonvulsant præparat som indeholder aminosyrederivat samt anvendelse af aminosyrederivater til frems

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040701

Year of fee payment: 13

LAPS Lapse due to unpaid annual fee